- Home
- SRZN vs OMIC Comparison
SRZN vs OMIC Comparison
Compare SRZN & OMIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- OMIC
- Stock Information
- Founded
- SRZN 2015
- OMIC 2016
- Country
- SRZN United States
- OMIC United States
- Employees
- SRZN N/A
- OMIC N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- OMIC Medical/Dental Instruments
- Sector
- SRZN Health Care
- OMIC Health Care
- Exchange
- SRZN Nasdaq
- OMIC Nasdaq
- Market Cap
- SRZN 38.1M
- OMIC 34.9M
- IPO Year
- SRZN N/A
- OMIC 2021
- Fundamental
- Price
- SRZN $9.10
- OMIC $22.98
- Analyst Decision
- SRZN
- OMIC Hold
- Analyst Count
- SRZN 0
- OMIC 2
- Target Price
- SRZN N/A
- OMIC $10.75
- AVG Volume (30 Days)
- SRZN 30.0K
- OMIC 35.1K
- Earning Date
- SRZN 11-06-2024
- OMIC 11-12-2024
- Dividend Yield
- SRZN N/A
- OMIC N/A
- EPS Growth
- SRZN N/A
- OMIC N/A
- EPS
- SRZN N/A
- OMIC N/A
- Revenue
- SRZN $10,000,000.00
- OMIC $2,723,000.00
- Revenue This Year
- SRZN N/A
- OMIC $10.41
- Revenue Next Year
- SRZN N/A
- OMIC $222.15
- P/E Ratio
- SRZN N/A
- OMIC N/A
- Revenue Growth
- SRZN N/A
- OMIC 27.66
- 52 Week Low
- SRZN $5.55
- OMIC $5.34
- 52 Week High
- SRZN $16.19
- OMIC $23.41
- Technical
- Relative Strength Index (RSI)
- SRZN 40.89
- OMIC 72.38
- Support Level
- SRZN $8.90
- OMIC $21.56
- Resistance Level
- SRZN $14.18
- OMIC $23.00
- Average True Range (ATR)
- SRZN 1.28
- OMIC 1.19
- MACD
- SRZN -0.26
- OMIC 0.64
- Stochastic Oscillator
- SRZN 3.87
- OMIC 92.01
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About OMIC Singular Genomics Systems Inc.
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.